Repare Announces Completion of Acquisition by XenoTherapeutics

London – January 28, 2026 – Cooley advised Repare Therapeutics, a clinical-stage precision oncology company enabled by its proprietary synthetic-lethality approach to discovering and developing novel therapeutics, on the completion of its acquisition of all issued and outstanding common shares by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly Xeno), a nonprofit biotechnology company, by way of a statutory plan of arrangement.

Under the terms of the arrangement, shareholders of Repare’s common shares received a cash payment of approximately $2.20 per common share, calculated based upon Repare’s cash balance immediately prior to closing, after deducting certain transaction costs, the aggregate amount of outstanding liabilities and a transaction fee to Xeno.

Lawyers Courtney Thorne, Rita Sobral, Div Gupta, Kevin Cooper, Christophe Beauduin, Peter Adams, Trevor Bossi, Kyle Hess, Sydney Sawyier, Margaux Wishart, Aaron Pomeroy, Rick Jantz and Reid Hooper led the Cooley team advising Repare as US counsel, alongside Stikeman Elliott LLP, which advised as Canadian counsel to Repare.

Cooley previously advised Repare as US counsel on its $253 million initial public offering in June 2020 and its $88 million follow-on offering in October 2021.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.